AstraZeneca, as part of its ongoing $3.5 billion investment in American innovation, opened its first U.S.-operated cell therapy factory in Maryland to help treat cancer patients. The U.K-based ...

HEADQUARTERS IN ROCKVILLE. THIS LAB ISN’T OPEN OR OPERATIONAL YET, BUT ONCE IT IS, THE FOLKS AT ASTRAZENECA BELIEVE IT IS GOING TO REVOLUTIONIZE CANCER TREATMENT. IT GIVES US HOPE. I MEAN.

AstraZeneca starts at 23.1 times in 2025 and gradually falls to 16.6 times by 2027. This indicates the market expects solid growth from AstraZeneca. GSK, on the other hand, has a much lower P/E ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...

Most importantly, Lefkofsky added, a substantial portion of the computing costs will be covered by AstraZeneca and Pathos AI. Lefkofsky says that the model is expected to be completed within 9 to ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

What was a commonly known secret finally became official Wednesday when the Utah Hockey Club unveiled its new nickname, the Mammoth, and its logo. Last week, the Utah Mammoth name was shown on the ...

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the company is a “little late to join the party.” But just because AZ has ...